{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:55:40Z","timestamp":1788357340741,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T00:00:00Z","timestamp":1729987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jaip.2024.10.024","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T11:21:31Z","timestamp":1730287291000},"page":"298-307.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Longitudinal Assessment of Glucocorticoid Toxicity Reduction in Patients With Severe Asthma Treated With Biologic Therapies"],"prefix":"10.1016","volume":"13","author":[{"given":"P. Jane","family":"McDowell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Busby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire A.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam G.","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.10.024_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.semarthrit.2020.09.016","article-title":"The story behind the use of glucocorticoids in the treatment of rheumatoid arthritis","volume":"51","author":"Conn","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaip.2024.10.024_bib2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.1950.02920160001001","article-title":"The effect of cortisone and pituitary adrenocorticotropic hormone (ACTH) on rheumatic diseases","volume":"144","author":"Hench","year":"1950","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2024.10.024_bib3","first-page":"803","article-title":"report to the Medical Research Council by the subcommittee on clinical trials in asthma","volume":"271","year":"1956","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2024.10.024_bib4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0140-6736(72)91094-X","article-title":"Effect of beclomethasone dipropionate delivered by aerosol in patients with asthma","volume":"1","author":"Clark","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2024.10.024_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/1817-1737.140120","article-title":"Corticosteroids in the treatment of acute asthma","volume":"9","author":"Alangari","year":"2014","journal-title":"Ann Thorac Med"},{"key":"10.1016\/j.jaip.2024.10.024_bib6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the international severe asthma registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2024.10.024_bib7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/thoraxjnl-2020-215168","article-title":"Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era","volume":"76","author":"Jackson","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2024.10.024_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01163-2019","article-title":"Characteristics and treatment regimens across ERS SHARP severe asthma registries","volume":"55","author":"van Bragt","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.10.024_bib9","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.10.024_bib10","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.10.024_bib11","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2024.10.024_bib12","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.10.024_bib13","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.10.024_bib14","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.10.024_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jaip.2020.08.032","article-title":"Quantification of glucocorticoid-associated morbidity in severe asthma using the Glucocorticoid Toxicity Index","volume":"9","author":"McDowell","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.10.024_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00160-2021","article-title":"Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index","volume":"59","author":"McDowell","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.10.024_bib17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.10.024_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2024.10.024_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152010","article-title":"The Glucocorticoid Toxicity Index: measuring change in glucocorticoid toxicity over time","volume":"55","author":"Stone","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaip.2024.10.024_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.10.024_bib21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/09612033231160969","article-title":"Estimating glucocorticoid-related morbidity in lupus nephritis using the Glucocorticoid Toxicity Index","volume":"32","author":"Usiskin","year":"2023","journal-title":"Lupus"},{"key":"10.1016\/j.jaip.2024.10.024_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jdin.2021.09.003","article-title":"Evaluation of the toxicity of glucocorticoids in patients with autoimmune blistering disease using the Glucocorticoid Toxicity Index: a cohort study","volume":"6","author":"Liang","year":"2022","journal-title":"JAAD Int"},{"key":"10.1016\/j.jaip.2024.10.024_bib23","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.jaip.2022.04.014","article-title":"Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma - first initiators and switchers","volume":"10","author":"Hashimoto","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.10.024_bib24","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.jaip.2023.05.025","article-title":"Long-term real-world outcomes of mepolizumab and benralizumab among biologic-na\u00efve patients with severe eosinophilic asthma: experience of 3 years\u2019 therapy","volume":"11","author":"Fyles","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Practi"},{"key":"10.1016\/j.jaip.2024.10.024_bib25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thorax-2021-217032","article-title":"Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study","volume":"78","author":"Soremekun","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2024.10.024_bib26","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1111\/all.15473","article-title":"Biologics and airway remodeling in severe asthma","volume":"77","author":"Varricchi","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.10.024_bib28","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01509-2019","article-title":"Targeting treatable traits in severe asthma: a randomised controlled trial","volume":"55","author":"McDonald","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.10.024_bib29","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.rmed.2005.02.013","article-title":"Prevalence of psychiatric morbidity in a difficult asthma population: relationship to asthma outcome","volume":"99","author":"Heaney","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2024.10.024_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.rmed.2009.08.005","article-title":"Close correlation between anxiety, depression, and asthma control","volume":"104","author":"Di Marco","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2024.10.024_bib31","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eu Respir J"},{"key":"10.1016\/j.jaip.2024.10.024_bib32","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.10.024_bib33","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.10.024_bib34","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"29","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.10.024_bib35","article-title":"Real-world application of the pediatric Glucocorticoid Toxicity Index in childhood-onset","volume":"68","author":"Zhang","year":"2024","journal-title":"lupus. Semin Arthritis Rheum"},{"key":"10.1016\/j.jaip.2024.10.024_bib36","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and validation of a questionnaire to measure asthma control","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.10.024_bib37","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.rmed.2005.08.012","article-title":"Identifying \u201cwell-controlled\u201d and \u201cnot well-controlled\u201d asthma using the Asthma Control Questionnaire","volume":"100","author":"Juniper","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2024.10.024_bib39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1034\/j.1399-3003.1999.14a08.x","article-title":"Development and validation of the Mini Asthma Quality of Life Questionnaire","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.10.024_bib40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George\u2019s Respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.jaip.2024.10.024_bib41","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jaip.2024.10.024_bib42","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.rmed.2005.02.013","article-title":"Prevalence of psychiatric morbidity in a difficult asthma population: relationship to asthma outcome","volume":"99","author":"Heaney","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2024.10.024_bib43","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.10.024_bib48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824010791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824010791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T03:08:28Z","timestamp":1744686508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219824010791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2213219824010791"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.10.024","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal Assessment of Glucocorticoid Toxicity Reduction in Patients With Severe Asthma Treated With Biologic Therapies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}